Difficulties in preventive therapy of tuberculosis infection in patients with severe autoimmune pathology during long-term immunosupressive treatment
https://doi.org/10.54921/2413-0346-2024-12-2-25-29
Abstract
Aim. To assess the state of vital organs in patients with severe autoimmune pathology before starting preventive therapy of tuberculosis infection.
Methods. Medical records, clinical and laboratory examination results were analysed in 38 patients with severe autoimmune diseases receiving long-term immunosuppressive therapy, which are referred to the TB dispensary to exclude tuberculosis infection. The frequency and severity of comorbid pathology, haematological and biochemical blood parameters before the start of preventive therapy of tuberculosis were assessed.
Results. indications for preventive therapy were determined in 37 (97.4%) patients: residual post-tuberculosis changes were detected in 7 (18.4%), latent tuberculosis infection in 30 (78.9%). A high frequency of significant concomitant pathology (on average 4.63 comorbidities per patient) with predominance of gastrointestinal (54.1%), visual (54.1%) and musculoskeletal (75.7%) diseases was revealed, which required individualisation of preventive therapy schemes and correction of drug doses. After a single 3-month course of preventive therapy, 27% of patients did not experience fading of the skin test with a recombinant tuberculosis allergen; 32.4% of patients still had hyperergic results.
Conclusion. Preventive therapy of tuberculosis infection in patients with severe autoimmune pathology requires a personalized approach with individual selection of regimens and doses of drugs used, careful clinical and laboratory monitoring, followed by long-term follow-up and assessment of the need for repeated preventive courses.
About the Authors
T. Yu. SalinaRussian Federation
Saratov
T. I. Morozova
Russian Federation
Saratov
References
1. Горлова Е.Е. Патология иммунитета при туберкулезе (обзор литературы) // Бюл. физиологии и патологии дыхания. – 2010. – № 35. – С. 37-44.
2. Клинические рекомендации «Туберкулез у взрослых» / Утв. Минздравом России. – М., 2022. – 151 с. https://gonktb.mznso.ru/media/cms_page_media/5893/klin-rek-tub-vzroslyih-2022_1.pdf
3. Acevedo-Vásquez E., Ponce de León D., Gamboa-Cárdenas R. Latent infection and tuberculosis disease in rheumatoid arthritis patients // Rheum. Dis. Clin. North Am. – 2009. – Vol. 35, № 1. – Р. 163-181.
4. Assefa D.G., Bedru A., Zeleke E.D. et al. Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials // Arch. Public Health. – 2023. – Vol. 81, № 1. – P. 82. https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-023-01098-z
5. Athimni S., Slouma M., Dhahri R. et al. Tuberculosis infection under anti-TNF alpha treatment // Curr. Drug Saf. – 2022. – Vol. 17, № 3. – P. 235-240.
6. Bigio J., Viscardi A., Gore G., Matteelli A., Sulis G. A scoping review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations? // Eur. Respir. Rev. – 2023. – Vol. 32 (167). – 220127. https://doi.org/10.1183/16000617.0127-2022
7. Carmona L., Hernández-García C., Vadillo C. et al. Increased risk of tuberculosis in patients with rheumatoid arthritis // J. Rheumatol. – 2003. – Vol. 30, № 7. – P. 1436-1439.
8. Ji X., Hu L., Wang Y., Man S. et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials // Chin. Med. J. – 2022. – Vol. 135, № 4. – P. 409-415.
Review
For citations:
Salina T.Yu., Morozova T.I. Difficulties in preventive therapy of tuberculosis infection in patients with severe autoimmune pathology during long-term immunosupressive treatment. Tuberculosis and socially significant diseases. 2024;12(2):25-29. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-2-25-29